Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAddition: 177Lu-PSMA-617 + SoC vs SoC in mHSPC
NCT04720157Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 19
01
Overview
A Phase 3 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Novartis. Started Jun 2021; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04720157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720157.